A carregar...
Model‐Informed Drug Development for Everolimus Dosing Selection in Pediatric Infant Patients
Everolimus is currently approved in Europe as an adjunctive therapy for patients aged ≥ 2 years with tuberous sclerosis complex (TSC)–associated treatment‐refractory partial‐onset seizures, based on the EXIST‐3 study (NCT01713946) results. As TSC‐associated seizures can also affect children aged bet...
Na minha lista:
| Publicado no: | CPT Pharmacometrics Syst Pharmacol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7180003/ https://ncbi.nlm.nih.gov/pubmed/32150661 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12502 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|